(Q33405571)

26 July 2017

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies (English)

1 reference

26 July 2017

phase I clinical trial

0 references

9

Razelle Kurzrock

1 reference

26 July 2017

1

Aung Naing

1 reference

26 July 2017

3

Grace K Dy

1 reference

26 July 2017

10

Alex A Adjei

1 reference

26 July 2017

8

Gerald Fetterly

1 reference

26 July 2017

Roger Cohen

2

1 reference

26 July 2017

David S Hong

4

1 reference

26 July 2017

Lyn Dyster

5

1 reference

26 July 2017

David G Hangauer

6

1 reference

26 July 2017

Rudolf Kwan

7

1 reference

26 July 2017

30 January 2013

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

31

1 reference

26 July 2017

4

1 reference

26 July 2017

967-973

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-9929-8

26 July 2017

0 references

cites work

Src family kinases in tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Current status of SRC inhibitors in solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

An overview of current diagnosis and treatment in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Src family kinases and paclitaxel sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Invasive prostate carcinoma driven by c-Src and androgen receptor synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9929-8

Update on taxane development: new analogs and new formulations

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23361621

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The shady side of dasatinib

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23361621

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measuring response in solid tumors: unidimensional versus bidimensional measurement

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23361621

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-013-9929-8

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference